Protara Completes Enrollment in THRIVE-3 Phase 2b; Interim Results Still Expected in 4Q 2026

What happened

Protara Therapeutics has completed enrollment of the 24-patient Phase 2b open-label dose confirmation cohort of the THRIVE-3 trial evaluating IV Choline Chloride in patients dependent on parenteral support. The company reiterates that interim results from this cohort remain on track for the fourth quarter of 2026, a timeline consistent with prior guidance. While this milestone demonstrates operational execution and keeps the IV choline program on schedule, the enrollment of only 24 patients is a modest step in a registrational path that still faces significant regulatory uncertainty given the novel pharmacokinetic-based endpoint. Protara remains a binary, pre-revenue biotech with a market cap around $118 million and cash reserves of roughly $133 million, which will be consumed by ongoing losses and multiple clinical programs. The stock's recent doubling over the past year already reflects substantial optimism, and this news alone does not materially alter the risk-reward balance, especially with pivotal NMIBC data from ADVANCED-2 still the most critical value driver.

Implication

Completion of enrollment in the THRIVE-3 Phase 2b is a positive but incremental step that reduces one near-term execution risk for the IV choline program. However, the program's reliance on a PK-based endpoint and the small sample size mean the upcoming interim data will need to show clear and compelling results to convince investors of its approvability. The company's cash position provides runway through key catalysts, but sustained cash burn and likely future dilution remain important overhangs. The more consequential events for Protara are the ADVANCED-2 NMIBC readouts (Cohort A mid-2025, Cohort B end-2025) and STARBORN-1 pediatric LM updates, which have greater market-impact potential. Until those data arrive, the stock's risk/reward appears fairly balanced, and a disciplined approach favors waiting for stronger evidence of clinical differentiation.

Thesis delta

The thesis remains unchanged: Protara is a speculative, binary investment where value hinges on TARA-002 in NMIBC and pediatric LMs, with IV choline as a secondary optionality. The completion of THRIVE-3 Phase 2b enrollment is consistent with prior guidance and does not alter the probability of success or the overall risk profile. No shift in stance is warranted at this time; the stock continues to be rated WAIT.